Lyons TJ, French J
Headquarters USAF Human Systems Division,
Brooks Air Force Base, TX 78235.
Aviat Space Environ Med 1991
May;62(5):432-5
ABSTRACT
Modafinil, a novel stimulant which has several remarkable features that
distinguish it from other stimulants, has been developed by Lafon, a French
pharmaceutical company. Unlike the amphetamines, for example, modafinil is
reported to have minimal peripheral side effects at therapeutic doses. It also
appears to have a low abuse potential, does not interfere with normal sleep,
and does not seem to produce tolerance. It improves vigilance especially in
sleep-deprived subjects. It has been used clinically for up to 3 years in the
treatment of narcolepsy and idiopathic hypersomnia. It could be an ideal
replacement for amphetamine in short-term operations in which fatigue might
threaten the successful completion of a mission. We recommend that military
laboratories experienced in studying sustained performance include modafinil
or perhaps a more selective alpha 1 receptor agonist in their investigations.
